A review on Alzheimer's disease pathophysiology and its management: An update

Pharmacological Reports

Volumn 67, Issue 2, 2015, Pages 195-203

  Kumar, Anil ^a   Singh, Arti ^a   Ekavali, ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Beta amyloid; D aspartate receptor antagonist; N methyl; Neurofibrillary tangles

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE RECEPTOR; AMYLOID BETA PROTEIN; CASPASE INHIBITOR; CHOLINESTERASE INHIBITOR; GONADOTROPIN; HYPOCHOLESTEROLEMIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; NITRIC OXIDE SYNTHASE; SECRETASE; SEROTONIN RECEPTOR; TAU PROTEIN; MEMANTINE; NEW DRUG;

ALZHEIMER DISEASE; HUMAN; INTRACELLULAR SIGNALING; MICROTUBULE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; VACCINATION; DRUG EFFECTS; INFLAMMATION; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; PROCEDURES; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CHOLINESTERASE INHIBITORS; DRUGS, INVESTIGATIONAL; HUMANS; INFLAMMATION; MEMANTINE; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TAU PROTEINS;

EID: 84918591171     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.09.004     Document Type: Review

References (111)

1. R. Anand, K.D. Gill, and A.A. Mahdi Therapeutics of Alzheimer's disease: past, present and future Neuropharmacology 76 2014 27 50
2. Alzheimer's Association Alzheimer's disease facts and figures Alzheimers Dement 10 2 2014 47 92
3. J. Ramirez-Bermudez Alzheimer's disease: critical notes on the history of a medical concept Arch Med Res 43 8 2012 595 599
4. D.S. Auld, T.J. Kornecook, S. Bastianetto, and R. Quirion Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies Prog Neurobiol 68 3 2002 209 245
5. M.R. Farlow, M.L. Miller, and V. Pejovic Treatment options in Alzheimer's disease: maximizing benefit, managing expectations Dement Geriatr Cogn Disord 25 5 2008 408 422
6. A. Kurz, and R. Perneczky Novel insights for the treatment of Alzheimer's disease Prog Neuropsychopharmacol Biol Psychiatry 35 2 2011 373 379
7. A. Kumar, and S. Dogra Neuropathology and therapeutic management of Alzheimer's disease - an update Drugs Future 33 5 2008 433 446
8. J. Hardy The amyloid hypothesis for Alzheimer's disease: a critical reappraisal J Neurochem 110 4 2009 1129 1134
9. I. Dal Prà, A. Chiarini, L. Gui, B. Chakravarthy, R. Pacchiana, and E. Gardenal Do astrocytes collaborate with neurons in spreading the "infectious" Aβ and tau drivers of Alzheimer's disease? Neuroscientist 2014 1073858414529828
10. S. Salomone, F. Caraci, G.M. Leggio, J. Fedotova, and F. Drago New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Br J Clin Pharmacol 73 4 2012 504 517
11. H. Rosenmann Immunotherapy for targeting tau pathology in Alzheimers disease and tauopathies Curr Alzheimer Res 10 3 2013 217 228
12. D.S. Antanitus A theory of cortical neuron-astrocyte interaction Neuroscientist 4 3 1998 154 159
13. A.D. Roth, G. Ramírez, R. Alarcón, and R. Von Bernhardi Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation Biol Res 38 4 2005 381 387
14. D. Galimberti, L. Ghezzi, and E. Scarpini Immunotherapy against amyloid pathology in Alzheimer's disease J Neurol Sci 333 1 2013 50 54
15. S. Subasinghe, S. Unabia, C.J. Barrow, S.S. Mok, M.I. Aguilar, and D.H. Small Cholesterol is necessary both for the toxic effect of Aβ peptides on vascular smooth muscle cells and for Aβ binding to vascular smooth muscle cell membranes J Neurochem 84 3 2003 471 479
16. Y. Xu, J. Yan, P. Zhou, J. Li, H. Gao, and Y. Xia Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease Prog Neurobiol 97 1 2012 1 13
17. U. Armato, B. Chakravarthy, R. Pacchiana, and J.F. Whitfield Alzheimer's disease: an update of the roles of receptors, astrocytes and primary cilia Int J Mol Med 31 1 2013 3 10 [review]
18. K. Yasojima, E. McGeer, and P. McGeer Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain Brain Res 919 1 2001 115 121
19. H. Braak, and K. Del Tredici Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol 121 5 2011 589 595
20. E.E. Tuppo, and H.R. Arias The role of inflammation in Alzheimer's disease Int J Biochem Cell Biol 37 2 2005 289 305
21. Y.S. Eisele, U. Obermüller, G. Heilbronner, F. Baumann, S.A. Kaeser, and H. Wolburg Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis Science 330 6006 2010 980 982
22. M. Talantova, S. Sanz-Blasco, X. Zhang, P. Xia, M.W. Akhtar, and Okamoto S.-i. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss Proc Natl Acad Sci U S A 110 27 2013 2518 2527
23. G. Silvestrelli, A. Lanari, L. Parnetti, D. Tomassoni, and F. Amenta Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology Mech Ageing Dev 127 2 2006 148 157
24. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 6740 1999 173 177
25. B.V. Zlokovic Clearing amyloid through the blood-brain barrier J Neurochem 89 4 2004 807 811
26. A. Sagare, R. Deane, R.D. Bell, B. Johnson, K. Hamm, and R. Pendu Clearance of amyloid-β by circulating lipoprotein receptors Nat Med 13 9 2007 1029 1031
27. S.D. Yan, A. Bierhaus, P.P. Nawroth, and D.M. Stern RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation? J Alzheimers Dis 16 4 2009 833 843
28. A.K. Ghosh, M. Brindisi, and J. Tang Developing β-secretase inhibitors for treatment of Alzheimer's disease J Neurochem 120 1 2012 71 83
29. W.P. Chang, X. Huang, D. Downs, J.R. Cirrito, G. Koelsch, and D.M. Holtzman β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice FASEB J 25 2 2011 775 784
30. P.S. Aisen, S. Gauthier, S.H. Ferris, D. Saumier, D. Haine, and D. Garceau Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Al phase Study) Arch Med Sci 7 1 2011 102 111
31. K.A. DaSilva, M.E. Brown, J.E. Cousins, R.V. Rappaport, I. Aubert, and D. Westaway Scyllo-inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease Alzheimers Dement 5 4 2009 425
32. M. Janusz, and A. Zablocka Colostral proline-rich polypeptides - immunoregulatory properties and prospects of therapeutic use in Alzheimers disease Curr Alzheimer Res 7 4 2010 323 333
33. J.S. Jacobsen, T.A. Comery, R.L. Martone, H. Elokdah, D.L. Crandall, and A. Oganesian Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade Proc Natl Acad Sci U S A 105 25 2008 8754 8759
34. T. Saito, N. Iwata, S. Tsubuki, Y. Takaki, J. Takano, and S.-M. Huang Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation Nat Med 11 4 2005 434 439
35. E. Scarpini, G. Bruno, G. Zappalà, M. Adami, U. Richarz, and M. Gaudig Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial J Alzheimers Dis 26 2 2011 211 220
36. C. Hock, and R.M. Nitsch Clinical observations with AN-1792 using TAPIR analyses Neurodegener Dis 2 5 2006 273 276
37. J.A. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R.O. Weller Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report Nat Med 9 4 2003 448 452
38. L. Buée, T. Bussiere, V. Buée-Scherrer, A. Delacourte, and P.R. Hof Tau protein isoforms, phosphorylation and role in neurodegenerative disorders Brain Res Rev 33 1 2000 95 130
39. T. Engel, P. Goñi-Oliver, J.J. Lucas, J. Avila, and F. Hernández Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert J Neurochem 99 6 2006 1445 1455
40. B. Zhang, A. Maiti, S. Shively, F. Lakhani, G. McDonald-Jones, and J. Bruce Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model Proc Natl Acad Sci U S A 102 1 2005 227 231
41. K.R. Brunden, B. Zhang, J. Carroll, Y. Yao, J.S. Potuzak, and Hogan A.-M.L. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy J Neurosci 30 41 2010 13861 13866
42. I. Gozes NAP (davunetide) provides functional and structural neuroprotection Curr Pharm Des 17 10 2011 1040 1044
43. H. Atamna, A. Nguyen, C. Schultz, K. Boyle, J. Newberry, and H. Kato Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways FASEB J 22 3 2008 703 712
44. L.E. Rojo, J. Alzate-Morales, I.N. Saavedra, P. Davies, and R.B. Maccioni Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease J Alzheimers Dis 19 2 2010 573 589
45. E.E. Congdon, J.W. Wu, N. Myeku, Y.H. Figueroa, M. Herman, and P.S. Marinec Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo Autophagy 8 4 2012 609 622
46. M. Pfaffendorf, T. Bruning, H. Batink, and P. Van Zwieten The interaction between methylene blue and the cholinergic system Br J Pharmacol 122 1 1997 95 98
47. C. Giommarelli, V. Zuco, E. Favini, C. Pisano, F. Dal Piaz, and N. De Tommasi The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition Cell Mol Life Sci 67 6 2010 995 1004
48. Q.L. Ma, X. Zuo, F. Yang, O.J. Ubeda, D.J. Gant, and M. Alaverdyan Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice J Biol Chem 288 6 2013 4056 4065
49. X. Chai, S. Wu, T.K. Murray, R. Kinley, C.V. Cella, and H. Sims Passive immunization with anti-tau antibodies in two transgenic models reduction of tau pathology and delay of disease progression J Biol Chem 286 39 2011 34457 34467
50. D. Puzzo, A. Staniszewski, S.X. Deng, L. Privitera, E. Leznik, and S. Liu Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimer's disease mouse model J Neurosci 29 25 2009 8075 8086
51. Y.F. Cheng, C. Wang, H.-B. Lin, Y.F. Li, Y. Huang, and J.P. Xu Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats Psychopharmacology (Berl) 212 2 2010 181 191
52. S.H. Park, J.H. Kim, S.S. Bae, K.W. Hong, D.S. Lee, and J.Y. Leem Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid beta-induced cognitive deficits associated with decreased amyloid beta accumulation Biochem Biophys Res Commun 408 4 2011 602 608
53. W. Froestl, A. Muhs, and A. Pfeifer Cognitive enhancers (nootropics). Part 2: Drugs interacting with enzymes J Alzheimers Dis 33 3 2013 547 658
54. E.L. Schaeffer, V.J. De-Paula, E.R. da Silva, Novaes BdA, H.D. Skaf, and O.V. Forlenza Inhibition of phospholipase A2 in rat brain decreases the levels of total tau protein J Neural Transm 118 9 2011 1273 1279
55. T.G. Oliveira, R.B. Chan, H. Tian, M. Laredo, G. Shui, and A. Staniszewski Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits J Neurosci 30 49 2010 16419 16428
56. P.B. Watkins, H.J. Zimmerman, M.J. Knapp, S.I. Gracon, and K.W. Lewis Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease JAMA 271 13 1994 992 998
57. A. Maelicke, A. Hoeffle-Maas, J. Ludwig, A. Maus, M. Samochocki, and U. Jordis Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy J Mol Neurosci 40 1-2 2010 135 137
58. H.Y. Zhang, H. Yan, and X.C. Tang Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase Cell Mol Neurobiol 28 2 2008 173 183
59. A. Fisher Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease J Neurochem 120 1 2012 22 33
60. S. Collina, R. Gaggeri, A. Marra, A. Bassi, S. Negrinotti, and F. Negri Sigma receptor modulators: a patent review Expert Opin Ther Pat 23 5 2013 597 613
61. V. Echeverria, and R. Zeitlin Cotinine: a potential new therapeutic agent against Alzheimer's disease CNS Neurosci Ther 18 7 2012 517 523
62. R.A. Rissman, A.L. De Blas, and D.M. Armstrong GABAA receptors in aging and Alzheimer's disease J Neurochem 103 4 2007 1285 1292
63. A. Limon, J.M. Reyes-Ruiz, and R. Miledi GABAergic drugs and Alzheimer's disease Future Med Chem 3 2 2011 149 153
64. M. Marcade, J. Bourdin, N. Loiseau, H. Peillon, A. Rayer, and D. Drouin Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing J Neurochem 106 1 2008 392 404
65. D.A. Butterfield, and C.B. Pocernich The glutamatergic system and Alzheimer's disease CNS Drugs 17 9 2003 641 652
66. J.J. Miguel-Hidalgo, I.A. Paul, V. Wanzo, and P.K. Banerjee Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid β 1-40 Eur J Pharmacol 692 1 2012 38 45
67. R. Hellweg, Y. Wirth, W. Janetzky, and S. Hartmann Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD Int J Geriatr Psychiatry 27 6 2012 651 656
68. R. Ni, A. Marutle, and A. Nordberg Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain J Alzheimers Dis 33 3 2013 841 851
69. J.J. Rodriguez, H.N. Noristani, and A. Verkhratsky The serotonergic system in ageing and Alzheimer's disease Prog Neurobiol 99 1 2012 15 41
70. M.V. King, C.A. Marsden, and K.C. Fone A role for the 5-HT 1A, 5-HT 4 and 5-HT 6 receptors in learning and memory Trends Pharmacol Sci 29 9 2008 482 492
71. A. Patat, V. Parks, S. Raje, A. Plotka, D. Chassard, and F.L. Coz Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects Br J Clin Pharmacol 67 3 2009 299 308
72. G. Maher-Edwards, R. Dixon, J. Hunter, M. Gold, G. Hopton, and G. Jacobs SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study Int J Geriatr Psychiatry 26 5 2011 536 544
73. A. Gravius, J. Laszy, M. Pietraszek, K. Saghy, J. Nagel, and C. Chambon Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity Behav Pharmacol 22 2 2011 122 135
74. M. Motawaj, A. Burban, E. Davenas, and J.M. Arrang Activation of brain histaminergic neurotransmission: a mechanism for cognitive effects of memantine in Alzheimer's disease J Pharmacol Exp Ther 336 2 2011 479 487
75. P.L. Chazot Therapeutic potential of histamine H3 receptor antagonists in dementias Drug News Perspect 23 2 2010 99 103
76. J.D. Brioni, T.A. Esbenshade, T.R. Garrison, S.R. Bitner, and M.D. Cowart Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease J Pharmacol Exp Ther 336 1 2011 38 46
77. A.A. Othman, G. Haig, H. Florian, C. Locke, J. Zhang, and S. Dutta Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers Br J Clin Pharmacol 75 5 2013 1299 1311
78. P.J. Nathan, R. Boardley, N. Scott, A. Berges, P. Maruff, and T. Sivananthan The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimers disease: a preliminary investigation Curr Alzheimer Res 10 3 2013 240 251
79. O.P. Dall'Igna, P. Fett, M.W. Gomes, D.O. Souza, R.A. Cunha, and D.R. Lara Caffeine and adenosine A 2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice Exp Neurol 203 1 2007 241 245
80. D. Cottrell, G. Borthwick, M. Johnson, P. Ince, and D. Turnbull The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease Neuropathol Appl Neurobiol 28 5 2002 390 396
81. S. Baloyannis Dendritic pathology in Alzheimer's disease J Neurol Sci 283 1 2009 153 157
82. J. Lee, J.H. Boo, and H. Ryu The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start? Adv Drug Deliv Rev 61 14 2009 1316 1323
83. H. Gutzmann, and D. Hadler Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study J Neural Transm Suppl 54 1998 301 310
84. Y. Wen, W. Li, E.C. Poteet, L. Xie, C. Tan, and L.-J. Yan Alternative mitochondrial electron transfer as a novel strategy for neuroprotection J Biol Chem 286 18 2011 16504 16515
85. D.R. Galasko, E. Peskind, C.M. Clark, J.F. Quinn, J.M. Ringman, and G.A. Jicha Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures Arch Neurol 69 7 2012 836 841
86. M. Manczak, P. Mao, M.J. Calkins, A. Cornea, A.P. Reddy, and M.P. Murphy Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons J Alzheimers Dis 20 2010 609 631
87. N. Farina, M. Isaac, A.R. Clark, J. Rusted, and N. Tabet Vitamin E for Alzheimer's dementia and mild cognitive impairment Cochrane Database Syst Rev 2012 11
88. M.W. Dysken, P.D. Guarino, J.E. Vertrees, S. Asthana, M. Sano, and M. Llorente Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data Alzheimers Dement 10 1 2014 36 44
89. H. Javed, M. Khan, A. Ahmad, K. Vaibhav, M. Ahmad, and A. Khan Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type Neuroscience 210 2012 340 352
90. D.P. Cardinali, A.M. Furio, and L.I. Brusco Clinical aspects of melatonin intervention in Alzheimer's disease progression Curr Neuropharmacol 8 3 2010 218 227
91. N. Nicolakakis, T. Aboulkassim, B. Ongali, C. Lecrux, P. Fernandes, and P. Rosa-Neto Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor γ agonist J Neurosci 28 37 2008 9287 9296
92. M.P. Lichtenstein, P. Carriba, M.A. Baltrons, B. Wojciak-Stothard, J.R. Peterson, and A. García Secretase-independent and RhoGTPase/PAK/ERK-dependent regulation of cytoskeleton dynamics in astrocytes by NSAIDs and derivatives J Alzheimers Dis 22 4 2010 1135 1155
93. S.H. Choi, S. Aid, L. Caracciolo, S. Sakura Minami, T. Niikura, and Y. Matsuoka Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease J Neurochem 124 1 2013 59 68
94. L. Li, D. Cao, H. Kim, R. Lester, and K.i. Fukuchi Simvastatin enhances learning and memory independent of amyloid load in mice Ann Neurol 60 6 2006 729 739
95. J. Bösel, F. Gandor, C. Harms, M. Synowitz, U. Harms, and P.C. Djoufack Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones J Neurochem 92 6 2005 1386 1398
96. A.C.R. Fonseca, R. Resende, C.R. Oliveira, and C.M. Pereira Cholesterol and statins in Alzheimer's disease: current controversies Exp Neurol 223 2 2010 282 293
97. A.M. Barron, S.J. Fuller, G. Verdile, and R.N. Martins Reproductive hormones modulate oxidative stress in Alzheimer's disease Antioxid Redox Signal 8 11-12 2006 2047 2059
98. Y. Yue, L. Hu, J.M. Jiang, Y.H. Cheng, and X. Hong Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes Acta Pharmacol Sin 28 8 2007 1129 1135
99. P.H. Lu, D.A. Masterman, R. Mulnard, C. Cotman, B. Miller, and K. Yaffe Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men Arch Neurol 63 2 2006 177 185
100. J.C. Carroll, and R.E. Rosario The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease Curr Alzheimer Res 9 1 2012 18 34
101. M.E. Jönhagen Nerve growth factor treatment in dementia Alzheimer Dis Assoc Disord 14 1 2000 31 38
102. R. Allegri, and A. Guekht Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia Drugs Today (Barc) 48 2012 25 41
103. D.K. Lahiri, N.H. Zawia, N.H. Greig, K. Sambamurti, and B. Maloney Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model Biogerontology 9 6 2008 375 379
104. C. Nelson, H. Wengreen, R. Munger, and C. Corcoran Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health, and aging study J Nutr Health Aging 13 10 2009 899 905
105. A. Nikolaev, T. McLaughlin, D.D. O'Leary, and M. Tessier-Lavigne APP binds DR6 to trigger axon pruning and neuron death via distinct caspases Nature 457 7232 2009 981 989
106. J. Ross, D. Brough, R.M. Gibson, S.A. Loddick, and N.J. Rothwell A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat Neuropharmacology 53 5 2007 638 642
107. M. Cavas, and J.F. Navarro Effects of selective neuronal nitric oxide synthase inhibition on sleep and wakefulness in the rat Prog Neuropsychopharmacol Biol Psychiatry 30 1 2006 56 67
108. S.R. Jaffrey, H. Erdjument-Bromage, C.D. Ferris, P. Tempst, and S.H. Snyder Protein S-nitrosylation: a physiological signal for neuronal nitric oxide Nat Cell Biol 3 2 2001 193 197
109. C. Coban, S. Koyama, F. Takeshita, S. Akira, and K.J. Ishii Molecular and cellular mechanisms of DNA vaccines Hum Vaccin 4 6 2008 453 456
110. M. Bajda, N. Guzior, M. Ignasik, and B. Malawska Multi-target-directed ligands in Alzheimer's disease treatment Curr Med Chem 18 32 2011 4949 4975
111. M. Yogev-Falach, O. Bar-Am, T. Amit, O. Weinreb, and M.B. Youdim A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing FASEB J 20 12 2006 2177 2179